Healthcare Industry News:  Consensus Interferon 

Biopharmaceuticals Licensing

 News Release - September 23, 2009

BurnsAdler Partners With Three Rivers Pharmaceuticals to Commercialize Infergen(R) in Brazil and Chile

CHARLOTTE, NC and WARRENDALE, PA., Sept. 23 - (HSMN NewsFeed) - BurnsAdler Pharmaceuticals, Inc. ("BurnsAdler") announced today that it has entered into a long-term licensing and supply agreement with Three Rivers Pharmaceuticals, LLC ("Three Rivers") for the company's Infergen (interferon alfacon-1) product.

Infergen, or Consensus Interferon, is a unique, bio-optimized, selective and highly potent type 1 interferon alpha originally developed by Amgen and launched in the United States in 1997. Infergen is indicated for the treatment of chronic hepatitis C virus ("HCV") infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA. BurnsAdler intends to market Infergen in Brazil and Chile.

Bryan Somerville, President of BurnsAdler, remarked, "We are very pleased to enter into this long-term partnership with Three Rivers and to offer healthcare professionals in Brazil and Chile Infergen as a safe and effective treatment for their HCV patients. The very serious nature of chronic HCV infection makes the lack of an effective therapy for nonresponders and relapse patients a critical medical need. By introducing Infergen to these markets, physicians will have a viable and proven treatment alternative for their seriously ill patients."

Pat Kerrish, Executive Vice President of Business Development for Three Rivers, commented, "We are looking forward to entering the Brazilian and Chilean markets with BurnsAdler. This relationship supports 3RP's model of establishing partnerships with pharmaceutical companies for commercialization efforts outside the United States."

About BurnsAdler Pharmaceuticals, Inc.

BurnsAdler Pharmaceuticals, Inc. is a specialty pharmaceutical company that commercializes products throughout Latin America. Through relationships with product developers from the Unites States and Europe, BurnsAdler helps deliver world-class medicine to these challenging international markets. BurnsAdler's portfolio includes pharmaceutical products and medical devices used in oncology, gastroenterology, cardiovascular medicine, orthopedics, emergency medicine and other critical care settings.

About Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals is a privately held company headquartered in Warrendale, Pennsylvania and focuses on specialized therapies including hepatitis C therapies. With its unique experience and understanding of the complex challenges of treating chronic, difficult diseases, Three Rivers is a valuable partner in the healthcare community. The company's mission is to develop, manufacture, and market the highest quality branded and generic drug products for patients with serious diseases. Three Rivers Pharmaceuticals focuses on specialized therapies because of our extensive knowledge and experience in this area. More information is available at

For additional information about this news release contact Carolina Cortez at (704) 552-8410 x225. For additional information about BurnsAdler, please refer to the company's website at

Source: BurnsAdler Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.